112 related articles for article (PubMed ID: 11484104)
1. Evaluation of long-term sequential changes in bone mass and strength following withdrawal of incadronate disodium (YM175) in ovariectomized rats.
Miyakoshi N; Sato K; Tamura Y; Tsuchida T; Kudo T; Kasukawa Y
J Orthop Sci; 2001; 6(2):167-76. PubMed ID: 11484104
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of withdrawal of bisphosphonate incadronate disodium (YM175) on bone mineral density, mass, structure, and turnover in the lumbar vertebrae of ovariectomized rats.
Tamura Y; Miyakoshi N; Itoi E; Abe T; Kudo T; Tsuchida T; Kasukawa Y; Sato K
J Bone Miner Res; 2001 Mar; 16(3):541-9. PubMed ID: 11277272
[TBL] [Abstract][Full Text] [Related]
3. Maintaining bone mass by bisphosphonate incadronate disodium (YM175) sequential treatment after discontinuation of intermittent human parathyroid hormone (1-34) administration in ovariectomized rats.
Takano Y; Tanizawa T; Mashiba T; Endo N; Nishida S; Takahashi HE
J Bone Miner Res; 1996 Feb; 11(2):169-77. PubMed ID: 8822340
[TBL] [Abstract][Full Text] [Related]
4. Effects of single and concurrent intermittent administration of human PTH (1-34) and incadronate on cancellous and cortical bone of femoral neck in ovariectomized rats.
Zhang L; Endo N; Yamamoto N; Tanizawa T; Takahashi HE
Tohoku J Exp Med; 1998 Oct; 186(2):131-41. PubMed ID: 10223616
[TBL] [Abstract][Full Text] [Related]
5. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
[TBL] [Abstract][Full Text] [Related]
6. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey.
Müller R; Hannan M; Smith SY; Bauss F
J Bone Miner Res; 2004 Nov; 19(11):1787-96. PubMed ID: 15476578
[TBL] [Abstract][Full Text] [Related]
7. Sequential treatment with basic fibroblast growth factor and parathyroid hormone restores lost cancellous bone mass and strength in the proximal tibia of aged ovariectomized rats.
Wronski TJ; Ratkus AM; Thomsen JS; Vulcan Q; Mosekilde L
J Bone Miner Res; 2001 Aug; 16(8):1399-407. PubMed ID: 11499862
[TBL] [Abstract][Full Text] [Related]
8. Comparative therapeutic effects of alendronate and alfacalcidol on cancellous and cortical bone mass and mechanical properties in ovariectomized osteopenic rats.
Iwamoto J; Seki A; Takeda T; Sato Y; Yamada H; Yeh JK
J Nutr Sci Vitaminol (Tokyo); 2006 Feb; 52(1):1-8. PubMed ID: 16637224
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats.
Iwamoto J; Seki A; Takeda T; Sato Y; Yamada H; Yeh JK
Exp Anim; 2006 Jul; 55(4):357-67. PubMed ID: 16880683
[TBL] [Abstract][Full Text] [Related]
10. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
[TBL] [Abstract][Full Text] [Related]
11. Effect of combined teriparatide and monthly minodronic acid therapy on cancellous bone mass in ovariectomized rats: a bone histomorphometry study.
Iwamoto J; Seki A; Sato Y
Bone; 2014 Jul; 64():88-94. PubMed ID: 24727162
[TBL] [Abstract][Full Text] [Related]
12. Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH.
Iwaniec UT; Samnegård E; Cullen DM; Kimmel DB
Bone; 2001 Oct; 29(4):352-60. PubMed ID: 11595618
[TBL] [Abstract][Full Text] [Related]
13. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat.
Gasser JA; Ingold P; Venturiere A; Shen V; Green JR
J Bone Miner Res; 2008 Apr; 23(4):544-51. PubMed ID: 18072878
[TBL] [Abstract][Full Text] [Related]
14. Short-term prophylaxis against estrogen depletion-induced bone loss with calcitriol does not provide long-term beneficial effects on cancellous bone mass or structure in ovariectomized rats.
Erben RG; Bromm S; Stangassinger M
Osteoporos Int; 1998; 8(1):82-91. PubMed ID: 9692082
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate tiludronate increases bone strength by improving mass and structure in established osteopenia after ovariectomy in rats.
Ohnishi H; Nakamura T; Narusawa K; Murakami H; Abe M; Barbier A; Suzuki K
Bone; 1997 Oct; 21(4):335-43. PubMed ID: 9315337
[TBL] [Abstract][Full Text] [Related]
16. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
[TBL] [Abstract][Full Text] [Related]
17. No loss of biomechanical effects after withdrawal of short-term PTH treatment in an aged, osteopenic, ovariectomized rat model.
Mosekilde L; Thomsen JS; McOsker JE
Bone; 1997 May; 20(5):429-37. PubMed ID: 9145240
[TBL] [Abstract][Full Text] [Related]
18. One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.
Varela A; Chouinard L; Lesage E; Guldberg R; Smith SY; Kostenuik PJ; Hattersley G
Bone; 2017 Feb; 95():143-150. PubMed ID: 27894941
[TBL] [Abstract][Full Text] [Related]
19. Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats.
Bourrin S; Ammann P; Bonjour JP; Rizzoli R
Bone; 2002 Jan; 30(1):195-200. PubMed ID: 11792585
[TBL] [Abstract][Full Text] [Related]
20. Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomized rats.
Wronski TJ; Dann LM; Qi H; Yen CF
Calcif Tissue Int; 1993 Sep; 53(3):210-6. PubMed ID: 8242475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
